Senate Panel Keeps DC Sales Rider, Backs Drug Testing Language
A Senate appropriations panel moved to maintain the ban on DC marijuana sales while urging federal agencies to preserve cannabis drug testing if rescheduling proceeds.

Classic view of the historic US Capitol Building in Washington, DC, with a clear blue sky.
Senate panel keeps the DC sales block and adds a drug-testing push
The Senate panel's spending language does two things at once: it leaves the DC sales restriction in place and tells federal agencies not to drop cannabis testing.
That's the extent of what the signal confirms. The Marijuana Moment headline, published November 19, 2026, describes a Senate panel that wants to keep blocking DC from legal marijuana sales while pushing federal agencies to continue cannabis drug testing under rescheduling.
We have only the headline and a truncated feed excerpt. Bill numbers, committee names, report-language text and vote counts aren't in hand, so none are stated here. Treat details beyond the headline as unconfirmed until the committee documents are read.
The DC rider has outlived legalization itself
DC voters approved Initiative 71 in 2014, but a congressional appropriations rider has barred the District from spending funds to set up a regulated retail market.
The result is a well-known oddity. Possession and home cultivation are legal in the District. A licensed, taxed system for sales isn't, and the gray market of 'gifting' shops filled the gap.
Congress has renewed the rider again and again in spending bills. A Senate panel keeping it in place suggests that pattern is holding, though final language will be set in whatever package ultimately reaches the floor. For the DC Council and anyone who has modeled a regulated District market, the practical answer is the same as it has been. Not yet.
Why drug testing language matters under rescheduling
Moving marijuana from Schedule I to Schedule III would not, by itself, change workplace or federal testing programs, and appropriators appear to want that spelled out.
Federal drug testing rules, including the Department of Transportation's regime and the broader federal workplace program, test for marijuana metabolites. Rescheduling raises an obvious question: does a Schedule III substance still belong on the panel? Appropriators pushing agencies to continue testing are signaling that the answer should be yes.
Employers and safety-sensitive industries have a stake in that framing. A rescheduling rule changes how the Controlled Substances Act treats the plant, but it doesn't automatically rewrite testing protocols. Report language like this is one way Congress tries to lock in continuity.
The chemistry behind the testing fight
Standard urine screens detect THC-COOH, a metabolite of delta-9 THC, and they cannot reliably tell a hemp-derived exposure from a marijuana one.
Here the hemp question intrudes. Federal law defines hemp by a 0.3 percent delta-9 THC threshold on a dry-weight basis. Smokable flower high in THCA can meet that definition at the farm gate, then convert to delta-9 THC through decarboxylation when heated. The metabolite a lab sees afterward is the same one.
So a testing mandate sits uneasily next to a hemp market built on that delta-9-versus-total-THC distinction. An employee who consumed a legal hemp product can still trigger a positive result. Whether any rescheduling-era testing guidance addresses that gap isn't something this signal tells us.
What operators and employers should take from it
Nothing in this development changes compliance obligations today, but it points toward continuity in testing and in the DC retail ban.
- DC businesses should keep planning around the gray market, not a licensed one.
- Employers with federally regulated workforces should assume testing panels stay in place.
- Hemp and THCA sellers should expect testing language to be cited against their products, not for them.
Committee report language is not law. Appropriations text can change in conference, and agencies retain discretion in how they implement it. That's a meaningful caveat, and the headline alone doesn't resolve it.
What we don't know yet
The source excerpt is truncated, so the specific bill, subcommittee and report language have not been verified.
We haven't seen the text that directs agencies on testing. Nor can we say whether it names specific programs or leaves the instruction general. How the rider interacts with the status of any pending rescheduling action is also unclear.
For full background on the rider's history, see the CannIntel topic hub on the DC marijuana sales appropriations rider. Our reporting will update once the committee text is in hand.
The testing question and the hemp-loophole question are headed for the same collision. Nothing here is settled, and enforcement will likely vary by agency and by employer.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Laws

Himachal Pradesh Issues Two Cannabis Cultivation Licences for FY27
Himachal Pradesh has moved to allow legal cannabis cultivation, issuing two licences for FY27, though the public record behind the licences remains thin.

Medical Marijuana Firms Sue DEA Over Rescheduling Restrictions
A federal lawsuit challenges conditions the DEA attached to rescheduling-related protections, putting licensed medical cannabis operators and the agency on a collision course in court.

Indiana's New Secretary of State Backs Voter Marijuana Referendum
Indiana's incoming secretary of state says residents should decide marijuana legalization at the ballot box, but the state has no initiative process to put it there.
More from the newsroom

Hawaii Senator Says Rescheduling Could Open Hospitals to Medical Marijuana
A Hawaii state senator told The Marijuana Herald that federal rescheduling may remove the compliance barrier keeping hospitals from allowing patients to use medical cannabis on-site.

Corning to vote on Sunday cannabis dispensary hours
A local vote in Steuben County will decide whether licensed dispensaries can open Sundays, a small test of how New York towns police retail hours.

Verano Opens MÜV Tarpon Springs, Its 89th Florida Dispensary
Verano's third new Florida store in a month lands ahead of Green Wednesday and Black Friday, extending the largest footprint in the Sunshine State's medical market.